Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.50M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50M | -- | -- | -- | -- |
| Cost of Revenue | 227.34M | 210.39M | 192.00M | 177.91M | 172.25M |
| Gross Profit | -219.84M | -210.39M | -192.00M | -177.91M | -172.25M |
| SG&A Expenses | 73.15M | 68.90M | 63.52M | 59.62M | 51.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 300.50M | 279.30M | 255.52M | 237.52M | 224.04M |
| Operating Income | -293.00M | -279.30M | -255.52M | -237.52M | -224.04M |
| Income Before Tax | -255.52M | -238.42M | -213.83M | -199.34M | -188.77M |
| Income Tax Expenses | -4.07M | -4.09M | -446.00K | -283.00K | -170.00K |
| Earnings from Continuing Operations | -251.45 | -234.33 | -213.39 | -199.06 | -188.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.45M | -234.33M | -213.39M | -199.06M | -188.60M |
| EBIT | -293.00M | -279.30M | -255.52M | -237.52M | -224.04M |
| EBITDA | -290.38M | -276.75M | -252.75M | -233.69M | -220.27M |
| EPS Basic | -3.22 | -3.01 | -2.81 | -2.74 | -2.71 |
| Normalized Basic EPS | -2.04 | -1.91 | -1.76 | -1.72 | -1.71 |
| EPS Diluted | -3.22 | -3.01 | -2.81 | -2.74 | -2.71 |
| Normalized Diluted EPS | -2.04 | -1.91 | -1.76 | -1.72 | -1.71 |
| Average Basic Shares Outstanding | 312.67M | 311.58M | 303.16M | 291.24M | 279.43M |
| Average Diluted Shares Outstanding | 312.67M | 311.58M | 303.16M | 291.24M | 279.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |